Envestnet Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.8M | Buy |
40,350
+5,774
| +17% | +$1.36M | ﹤0.01% | 1776 |
|
|
2026
Q1 | $6.9M | Buy |
34,576
+6,841
| +25% | +$1.35M | ﹤0.01% | 2084 |
|
|
2025
Q4 | $5.24M | Sell |
27,735
-4,180
| -13% | -$803K | ﹤0.01% | 2139 |
|
|
2025
Q3 | $5.65M | Buy |
31,915
+4,538
| +17% | +$675K | ﹤0.01% | 2154 |
|
|
2025
Q2 | $3.11M | Buy |
27,377
+769
| +3% | +$82.2K | ﹤0.01% | 2523 |
|
|
2025
Q1 | $2.8M | Sell |
26,608
-60,587
| -69% | -$6.85M | ﹤0.01% | 2505 |
|
|
2024
Q4 | $9.34M | Buy |
87,195
+910
| +1% | +$103K | ﹤0.01% | 1698 |
|
|
2024
Q3 | $8.64M | Buy |
86,285
+6,673
| +8% | +$672K | ﹤0.01% | 1736 |
|
|
2024
Q2 | $6.71M | Buy |
79,612
+25,717
| +48% | +$2.05M | ﹤0.01% | 1825 |
|
|
2024
Q1 | $3.94M | Buy |
53,895
+8,775
| +19% | +$647K | ﹤0.01% | 2140 |
|
|
2023
Q4 | $3.22M | Buy |
45,120
+1,332
| +3% | +$78.6K | ﹤0.01% | 2172 |
|
|
2023
Q3 | $2.62M | Buy |
43,788
+5,916
| +16% | +$389K | ﹤0.01% | 2217 |
|
|
2023
Q2 | $2.73M | Sell |
37,872
-34,423
| -48% | -$2.58M | ﹤0.01% | 2085 |
|
|
2023
Q1 | $2.37M | Buy |
72,295
+41,784
| +137% | +$2.97M | ﹤0.01% | 2086 |
|
|
2022
Q4 | $2.04M | Sell |
30,511
-17,882
| -37% | -$1.16M | ﹤0.01% | 2153 |
|
|
2022
Q3 | $2.6M | Buy |
48,393
+5,724
| +13% | +$336K | ﹤0.01% | 1922 |
|
|
2022
Q2 | $2.38M | Buy |
42,669
+4,954
| +13% | +$281K | ﹤0.01% | 1998 |
|
|
2022
Q1 | $2.65M | Buy |
37,715
+3,117
| +9% | +$226K | ﹤0.01% | 2038 |
|
|
2021
Q4 | $3.33M | Buy |
34,598
+8,705
| +34% | +$804K | ﹤0.01% | 1842 |
|
|
2021
Q3 | $2.25M | Buy |
25,893
+1,659
| +7% | +$128K | ﹤0.01% | 2020 |
|
|
2021
Q2 | $1.98M | Buy |
24,234
+7,935
| +49% | +$660K | ﹤0.01% | 2061 |
|
|
2021
Q1 | $1.55M | Sell |
16,299
-5,303
| -25% | -$501K | ﹤0.01% | 2102 |
|
|
2020
Q4 | $1.34M | Sell |
21,602
-15,400
| -42% | -$878K | ﹤0.01% | 2012 |
|
|
2020
Q3 | $2.2M | Buy |
37,002
+4,400
| +13% | +$300K | ﹤0.01% | 1567 |
|
|
2020
Q2 | $2.27M | Buy |
32,602
+239
| +0.7% | +$15.2K | ﹤0.01% | 1495 |
|
|
2020
Q1 | $1.47M | Buy |
32,363
+6,399
| +25% | +$363K | ﹤0.01% | 1578 |
|
|
2019
Q4 | $1.69M | Sell |
25,964
-6,311
| -20% | -$422K | ﹤0.01% | 1710 |
|
|
2019
Q3 | $2M | Sell |
32,275
-1,109
| -3% | -$69.6K | ﹤0.01% | 1539 |
|
|
2019
Q2 | $2.38M | Buy |
33,384
+4,928
| +17% | +$363K | ﹤0.01% | 1456 |
|
|
2019
Q1 | $2.23M | Buy |
28,456
+5,934
| +26% | +$450K | ﹤0.01% | 1421 |
|
|
2018
Q4 | $1.91M | Buy |
+22,522
| New | +$2.4M | ﹤0.01% | 1373 |
|
|
2018
Q3 | – | Sell |
-9,264
| Closed | -$1.2M | – | 2002 |
|
|
2018
Q2 | $1.2M | Sell |
9,264
-192
| -2% | -$21.4K | ﹤0.01% | 994 |
|
|
2018
Q1 | $968K | Sell |
9,456
-1,335
| -12% | -$132K | ﹤0.01% | 964 |
|
|
2017
Q4 | $922K | Buy |
10,791
+123
| +1% | +$10.7K | ﹤0.01% | 1239 |
|
|
2017
Q3 | $905K | Buy |
10,668
+1,295
| +14% | +$103K | ﹤0.01% | 1204 |
|
|
2017
Q2 | $709K | Buy |
9,373
+137
| +1% | +$9.58K | ﹤0.01% | 1336 |
|
|
2017
Q1 | $610K | Buy |
9,236
+511
| +6% | +$33.6K | ﹤0.01% | 1424 |
|
|
2016
Q4 | $551K | Buy |
8,725
+994
| +13% | +$62.7K | ﹤0.01% | 1455 |
|
|
2016
Q3 | $492K | Sell |
7,731
-419
| -5% | -$30.8K | ﹤0.01% | 1573 |
|
|
2016
Q2 | $606K | Buy |
8,150
+427
| +6% | +$31.7K | ﹤0.01% | 1564 |
|
|
2016
Q1 | $516K | Buy |
7,723
+1,317
| +21% | +$80K | ﹤0.01% | 1617 |
|
|
2015
Q4 | $433K | Buy |
6,406
+1,031
| +19% | +$63.7K | ﹤0.01% | 1670 |
|
|
2015
Q3 | $287K | Buy |
5,375
+2,095
| +64% | +$127K | ﹤0.01% | 1857 |
|
|
2015
Q2 | $206K | Buy |
+3,280
| New | +$179K | ﹤0.01% | 2120 |
|
|
2015
Q1 | – | Sell |
-692
| Closed | -$23K | – | 2247 |
|
|
2014
Q4 | $23K | Buy |
692
+46
| +7% | +$1.5K | ﹤0.01% | 1688 |
|
|
2014
Q3 | $19K | Buy |
646
+340
| +111% | +$11.3K | ﹤0.01% | 1903 |
|
|
2014
Q2 | $12K | Buy |
306
+142
| +87% | +$5.76K | ﹤0.01% | 1956 |
|
|
2014
Q1 | $7K | Buy |
+164
| New | +$6.84K | ﹤0.01% | 2007 |
|
Other funds holding LGND
JT
CAM
Envestnet Asset Management's LGND Position: Q2 2026 in Review
Envestnet Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 17% in Q2 2026, buying an estimated $1.36M and bringing the position to 40,350 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1776.
Envestnet Asset Management first reported a position in LGND in Q1 2014 and has held it in 48 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Envestnet Asset Management held 40,350 shares of Ligand Pharmaceuticals worth $12.8M as of Q2 2026.
- Envestnet Asset Management bought 5,774 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.36M.
- Ligand Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #1776 holding.
- Envestnet Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2014 and has held it in 48 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.